查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771507

全球藥物安全檢測市場：市場規模、佔有率、趨勢分析（按產品生命週期、服務供應商、類型、治療領域、流程、最終用途和地區）、細分市場預測（2025-2030 年）

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

藥物安全檢測市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，到 2030 年全球藥物安全檢測市場規模預計將達到 117.8 億美元。

預計2025年至2030年期間，該市場的複合年成長率將達到6.5%。市場成長的主要驅動力是藥物不良反應 (ADR) 發病率的上升。 ADR 給醫療保健系統帶來了巨大的負擔，並且是已開發國家疾病高發生率的明顯原因之一。根據美國生物技術資訊中心 (NCBI) 的數據，歐洲每年約有20例住院病例是由 ADR 引起的。藥物安全檢測(PV) 服務在協助製造商識別臨床試驗階段藥物相關不良反應方面發揮著至關重要的作用。

此外，2022年2月發表在《當代醫學研究與實踐雜誌》上的一篇題為《癌症化療患者不良反應嚴重性和結局的特徵——一項前瞻性觀察性研究》的論文顯示，嚴重的藥物不良反應每年在美國造成超過10萬人死亡，成為過去十年來的主要健康問題。致命的心律不整和肝功能衰竭等藥物不良反應可能導致藥物退出市場，因為使用這些藥物的風險大於其益處。新冠疫情為光電服務供應商帶來了機會和挑戰，促使他們開發創新平台來提升競爭力。

例如，2020年12月，生命科學產業的商業服務供應商EVERSANA與專注於藥物開發流程自動化的生命科學軟體公司ArisGlobal合作。此次合作旨在將端到端的藥物上市（PV）流程數位化，從而在全球範圍內實現更安全、更有效的醫療保健。預計在預測期內，對技術先進且方便用戶使用的軟體系統（例如雲端基礎的藥物上市和藥物安全平台）的需求將支撐產業成長。例如，Clinevo Technologies提供的Clinevo Safety是一款雲端基礎的解決方案，涵蓋案例處理、法規提交/AS2閘道器、藥物上市（PV）接收、分析和安全訊號等多種功能。

這種一體化平台正在推動市場發展。此外，協調一致的努力也支持巴西等新興市場的成長。例如，巴西推出了一項聯合病患安全和藥物警戒 (PV) 項目，涉及製藥業、學術界、臨床實踐和衛生當局。該計畫由巴西農業研究基金會 (FIPFARMA) 和聖保羅大學藥學院共同實施，分兩期（2020 年和 2022 年）推出了一門 30 小時的線上課程。課程涵蓋了醫療保健和藥物安全檢測概述、藥物安全和管理以及病人安全文化等重要主題。研討會探討了醫療保健專業人員 (HCP) 面臨的實際挑戰，並鼓勵協作解決問題。

視訊會議有效地吸引了醫護人員參與並進行了培訓，促進了知識共用，並促使思維方式轉變。該措施對參與者產生了積極影響，並提升了巴西的藥效學實踐。已開發國家的大型製藥公司正致力於外包藥效學服務，以降低成本和營運費用。這有望為開發中國家的合約研究組織 (CRO) 提供擴大其行業佔有率的機會。開發人員正在重新思考其產品委外研發機構，以滿足全球日益成長的患者需求。由於這些因素，預計在預測期內，對藥效學服務的需求將會成長。

此外，光伏產業參與者正在實施收購、合作、業務擴張和產品發布等策略，以拓寬產品供應並提升市場佔有率。例如，專注於製藥業的服務供應商Ergomed plc於2022年2月收購了ADAMAS Consulting Group Limited。 ADAMAS是一家國際顧問公司，為光電系統提供藥品製造、臨床試驗審核和品質保證服務。此次收購價值2,560萬英鎊，預計將增加Ergomed的收益，並在未來帶來進一步的成長和策略優勢。

藥物安全檢測市場：概述

  • 由於 ADR 事件和上市後監測的增加，IV 期在 2024 年佔據市場主導地位，收入佔有率超過 75.90%。
  • 在2024年的服務供應商領域中，合約外包領域佔據了最大的市場佔有率，因為製藥公司旨在透過外包服務來降低業務成本。
  • 自發報告部分在 2024 年佔據了藥物安全檢測市場的最大佔有率。其應用包括高效且經濟地檢測新型、嚴重和罕見的 ADR。
  • 在2024年的治療領域細分中，腫瘤學佔最大佔有率，超過27.14%，這得益於生物製藥公司在慢性癌症治療的研究力度。
  • 預測期內，案例資料管理預計將在流程流程領域中以最快的複合年成長率成長。
  • 由於生物技術公司專注於生技藥品、治療藥物和基因療法等新產品的研發，預計在預測期內生物技術公司部門的複合年成長率將最快。
  • 由於對開發新藥的投資、有利的法規以及強大的研究單位和臨床試驗的存在，北美將在 2024 年佔據最大的收益佔有率，超過 32.11%。
  • 公司正在採取新產品發布、合作和收購等策略來獲得競爭優勢。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章 市場促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 產業機會分析
    • 產業挑戰分析
  • 波特五力分析
    • 供應商權力
    • 買方力量
    • 替代威脅
    • 新進入者的威脅
    • 競爭對手之間的競爭
  • PESTLE分析
  • 價值鏈分析
    • 臨床前
    • 臨床
    • PMA
  • 繪製服務產品生命週期及其需求
  • 法律規範
    • 監理機關名單：依國家
  • 定價模式
    • 藥品安全預算依活動分配
    • 按開發階段
    • 按治療區域
    • 定價層
  • 技術時間軸概述
    • 技術變革與採用
    • 太陽能技術的現狀
    • IQVIA 的人工智慧主導的藥物安全檢測轉型
    • Tech Mahindra 的人工智慧驅動藥物安全檢測解決方案
    • AI輔助光電工作負載的演進
    • 社群媒體
  • COVID-19影響分析
    • 發展與策略成果
  • 市場趨勢：
    • 擴展資源
    • 藥物安全檢測自動化
  • 通貨膨脹的影響
  • 案例研究
    • 潛在客戶
    • 值得注意的用案例
    • 案例研究1
    • 案例研究2
    • 案例研究3
    • 案例研究4

第4章藥物安全檢測市場：按產品的估計和趨勢分析

  • 細分儀表板：依產品
  • 按產品分類的市場佔有率變化分析（2024 年和 2030 年）
  • 市場規模預測及產品趨勢分析（2018-2030）
    • 臨床前
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第5章藥物安全檢測市場：服務供應商的估計和趨勢分析

  • 細分儀表板：依服務供應商
  • 服務供應商市場佔有率變化分析（2024 年和 2030 年）
  • 服務供應商市場規模預測及趨勢分析（2018-2030）
  • 內部
    • 內部市場（2018-2030）
  • 合約外包
    • 合約外包市場（2018-2030）

第6章藥物安全檢測市場：按類型進行估計和趨勢分析

  • 細分儀表板：按類型
  • 按類型分類的市場佔有率變化分析（2024 年和 2030 年）
  • 按類型分類的市場規模預測和趨勢分析（2018-2030）
  • 自發性報告
  • 增強型 ADR 報告
  • 有針對性和自發性的報道
  • 群組心臟事件記錄器(CEM)
  • EHR挖掘

第7章藥物安全檢測市場：依流程進行評估與趨勢分析

  • 細分儀表板：依流程
  • 按製程流程分類的市場佔有率變化分析（2024 年和 2030 年）
  • 按製程流程分類的市場規模預測和趨勢分析（2018-2030）
  • 病例資料管理
  • 訊號檢測
  • 風險管理系統

第8章藥物安全檢測市場：按治療領域的估計和趨勢分析

  • 細分儀表板：按治療領域
  • 按治療領域分類的市場佔有率變化分析（2024 年和 2030 年）
  • 依治療領域分類的市場規模預測及趨勢分析（2018-2030年）
  • 瘤
    • 腫瘤學市場（2018-2030）
  • 神經病學
    • 神經病學市場（2018-2030）
  • 呼吸系統
    • 呼吸系統市場（2018-2030）
  • 其他
    • 其他市場（2018-2030）
  • 神經病學

第9章藥物安全檢測市場：按地區估計和趨勢分析

  • 市場儀表板：按地區
  • 各地區主要市場點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第 10 章藥物安全檢測市場：競爭分析

  • 市場參與企業分類
  • 上市公司
    • 企業市場分析
    • 公司市場佔有率分析
  • 競爭因素和策略
    • 增加策略合作和產品發布
    • 政府策略性舉措，包括合作
    • 競爭對手加強光電宣傳計劃
    • 競爭正在加強業務協作和外包
    • 整合趨勢

第11章競爭格局

  • 公司簡介
    • Accenture
    • IQVIA Inc.
    • Cognizant
    • Clinquest Group BV（Linical Americas）
    • IBM
    • Laboratory Corporation of America Holdings
    • ArisGlobal
    • Capgemini
    • ITClinical
    • ICON plc.
    • TAKE Solutions Limited
    • Parexel International（MA）Corporation
    • Wipro
    • United BioSource LLC
    • BioClinica Inc.（Clario）
    • ClinChoice（formerly FMD K&L）

第12章 制勝策略

  • 主要勝利/評分標準
    • 按類別
    • 供應商選擇的關鍵因素

第13章 轉換成本分析

Product Code: 978-1-68038-327-0

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.5% from 2025 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

  • Phase IV dominated the market with a revenue share of over 75.90% in 2024. This was driven by increased ADR incidents and post-marketing surveillance
  • contract outsourcing segment held the largest market share in in the service provider segment in 2024, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • Spontaneous reporting segment dominated the pharmacovigilance market in 2024 with the largest share. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 27.14% in the therapeutic area segment in 2024, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR in the process flow segment during the forecast period
  • The biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 32.11% in 2024 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Life Cycle
    • 1.2.2. Service Provider
    • 1.2.3. Type
    • 1.2.4. Process Flow
    • 1.2.5. Therapeutic area
    • 1.2.6. End use
    • 1.2.7. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
      • 1.5.4.1. Details of Primary Research
      • 1.5.4.2. Data for primary interviews in North America
      • 1.5.4.3. Data for Primary Interviews in Europe
      • 1.5.4.4. Data for Primary Interviews in APAC
      • 1.5.4.5. Data for Primary Interviews in Latin America
      • 1.5.4.6. Data for Primary Interviews in MEA
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Report Objectives
    • 1.10.1. Objective-1
    • 1.10.2. Objective-2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
    • 2.2.1. Segment Snapshot (Product Life Cycle & Type)
    • 2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
    • 2.2.3. Segment Snapshot (End Use)
    • 2.2.4. Competitive Landscape Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing drug consumption and drug development rates
      • 3.2.1.2. Increasing incidence of ADR and drug toxicity
      • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
      • 3.2.1.4. Increasing externalization of clinical trial studies by large
      • 3.2.1.5. Increasing Regulatory Burden on Manufacturers
      • 3.2.1.6. Introduction of technologically advanced software services
        • 3.2.1.6.1. Key focus areas for the pharmaceutical/healthcare companies
        • 3.2.1.6.2. Adoption of technological advancements in Life sciences industry
        • 3.2.1.6.3. Published Survey insights - related to adoption of pharmacovigilance automation
      • 3.2.1.7. Rising investment on R&D by healthcare companies
      • 3.2.1.8. Partnerships and collaborations between market players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Shortage of skilled labor
      • 3.2.2.2. Expensive technology for small and mid-sized player
      • 3.2.2.3. Lack of recognition
      • 3.2.2.4. Scarcity of integration standards
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Supplier power
    • 3.3.2. Buyer power
    • 3.3.3. Substitution threat
    • 3.3.4. Threat of new entrant
    • 3.3.5. Competitive rivalry
  • 3.4. PESTLE Analysis
  • 3.5. Value Chain Analysis
    • 3.5.1. Preclinical
    • 3.5.2. Clinical
    • 3.5.3. PMA
  • 3.6. Mapping of Life Cycle Against Service Offering and Their Demand
  • 3.7. Regulatory Framework
    • 3.7.1. List of regulatory bodies by Country
  • 3.8. Pricing Models
    • 3.8.1. Drug safety budget allocation by activities
    • 3.8.2. By development phase
    • 3.8.3. By therapeutic area
    • 3.8.4. Pricing level
      • 3.8.4.1. Project management
      • 3.8.4.2. Case processing
      • 3.8.4.3. ADR Reporting
      • 3.8.4.4. Medical writing
      • 3.8.4.5. Drug safety management
  • 3.9. Technology Timeline Overview
    • 3.9.1. Changing Technology & Adoption
    • 3.9.2. Current Technology Landscape of PV
    • 3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
    • 3.9.4. Tech Mahindra's AI-Driven Pharmacovigilance Solution in
    • 3.9.5. The evolving PV workload with AI assistance
    • 3.9.6. Social Media
      • 3.9.6.1. Literature screening
      • 3.9.6.2. Automation and AI
      • 3.9.6.3. Big data analytics in PV
  • 3.10. COVID 19 Impact Analysis
    • 3.10.1. Developments & Strategic Outcomes
      • 3.10.1.1. Regulatory requirements/changes due to covid-19
      • 3.10.1.2. Strategies implemented by companies
        • 3.10.1.2.1. IQVIA
        • 3.10.1.2.2. IBM Corporation
        • 3.10.1.2.3. ArisGlobal
        • 3.10.1.2.4. PAREXEL International Corporation
        • 3.10.1.2.5. Bioclinica
        • 3.10.1.2.6. Pharmaceutical Product Development (PPD)
        • 3.10.1.2.7. ICON, plc
        • 3.10.1.2.8. PRA Health Sciences
        • 3.10.1.2.9. Linical Accelovance
        • 3.10.1.2.10. Laboratory Corporation of America Holdings
  • 3.11. Market Trend:
    • 3.11.1. Scaling of resources
    • 3.11.2. Automation in Pharmacovigilance
  • 3.12. Impact of Inflation
  • 3.13. Case Studies
    • 3.13.1. Potential Customers
    • 3.13.2. Notable Use Cases
    • 3.13.3. Case Study 1
      • 3.13.3.1. Part 1
      • 3.13.3.2. Part 2
    • 3.13.4. Case Study 2
    • 3.13.5. Case Study 3
    • 3.13.6. Case Study 4

Chapter 4. Pharmacovigilance Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Product Market Share Movement Analysis, 2024 & 2030
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
    • 4.3.1. Preclinical
      • 4.3.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Phase I
      • 4.3.2.1. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Phase II
      • 4.3.3.1. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Phase III
      • 4.3.4.1. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Phase IV
      • 4.3.5.1. Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1. Service Provider Dashboard
  • 5.2. Service Provider Market Share Movement Analysis, 2024 & 2030
  • 5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
  • 5.4. In House
    • 5.4.1. In-house market, 2018 - 2030 (USD Million)
  • 5.5. Contract Outsourcing
    • 5.5.1. Contract Outsourcing market, 2018 - 2030 (USD Million)

Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1. Type Segment Dashboard
  • 6.2. Type Market Share Movement Analysis, 2024 & 2030
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 6.4. Spontaneous Reporting
    • 6.4.1. Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Intensified ADR Reporting
    • 6.5.1. Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Targeted Spontaneous Reporting
    • 6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Cohort Event Monitoring (CEM)
    • 6.7.1. CEM market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. EHR Mining
    • 6.8.1. EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1. Process Flow Segment Dashboard
  • 7.2. Process Flow Market Share Movement Analysis, 2024 & 2030
  • 7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2018 to 2030 (USD Million)
  • 7.4. Case data management
    • 7.4.1. Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.4.1.1. Case logging
        • 7.4.1.1.1. Case logging market, 2018 - 2030 (USD Million)
      • 7.4.1.2. Case data analysis
        • 7.4.1.2.1. Case data analysis market, 2018 - 2030 (USD Million)
      • 7.4.1.3. Medical reviewing and reporting
        • 7.4.1.3.1. Medical reviewing and reporting market, 2018 - 2030 (USD Million)
  • 7.5. Signal detection
    • 7.5.1. Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.5.1.1. Adverse Event Logging
        • 7.5.1.1.1. Adverse event logging market, 2018 - 2030 (USD Million)
      • 7.5.1.2. Adverse Event Analysis
        • 7.5.1.2.1. Adverse Event Analysis market, 2018 - 2030 (USD Million)
      • 7.5.1.3. Adverse Event Review & Reporting
        • 7.5.1.3.1. Adverse Event Review & Reporting market, 2018 - 2030 (USD Million)
  • 7.6. Risk Management System
    • 7.6.1. Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.6.1.1. Risk Evaluation System
        • 7.6.1.1.1. Risk Evaluation market, 2018 - 2030 (USD Million)
      • 7.6.1.2. Risk Mitigation System
        • 7.6.1.2.1. Risk Mitigation market, 2018 - 2030 (USD Million)

Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1. Therapeutic Area Segment Dashboard
  • 8.2. Therapeutic Area Market Share Movement Analysis, 2024 & 2030
  • 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 8.4. Oncology
    • 8.4.1. Oncology market, 2018 - 2030 (USD Million)
  • 8.5. Neurology
    • 8.5.1. Neurology market, 2018 - 2030 (USD Million)
  • 8.6. Respiratory Systems
    • 8.6.1. Respiratory Systems market, 2018 - 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Other market, 2018 - 2030 (USD Million)
  • 8.8. Neurology

Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Dashboard
  • 9.2. Regional Market: Key Takeaways
  • 9.3. North America
    • 9.3.1. North America Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamic
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive insights
      • 9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamic
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive insights
      • 9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2018 - 2030
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamic
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive insights
      • 9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamic
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive insights
      • 9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. UK
      • 9.4.3.1. Key country dynamic
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive insights
      • 9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamic
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive insights
      • 9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamic
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive insights
      • 9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamic
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive insights
      • 9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Russia
      • 9.4.7.1. Key country dynamic
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive insights
      • 9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.8. Denmark
      • 9.4.8.1. Key country dynamic
      • 9.4.8.2. Regulatory framework
      • 9.4.8.3. Competitive insights
      • 9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.9. Sweden
      • 9.4.9.1. Key country dynamic
      • 9.4.9.2. Regulatory framework
      • 9.4.9.3. Competitive insights
      • 9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.10. Norway
      • 9.4.10.1. Key country dynamic
      • 9.4.10.2. Regulatory framework
      • 9.4.10.3. Competitive insights
      • 9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key country dynamic
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive insights
      • 9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key country dynamic
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive insights
      • 9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamic
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive insights
      • 9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamic
      • 9.5.5.2. Regulatory framework
      • 9.5.5.3. Competitive insights
      • 9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.6. Australia
      • 9.5.6.1. Key country dynamic
      • 9.5.6.2. Regulatory framework
      • 9.5.6.3. Competitive insights
      • 9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.7. Thailand
      • 9.5.7.1. Key country dynamic
      • 9.5.7.2. Regulatory framework
      • 9.5.7.3. Competitive insights
      • 9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamic
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive insights
      • 9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 9.6.2.5. (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamic
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive insights
      • 9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key country dynamic
      • 9.7.2.2. Regulatory framework
      • 9.7.2.3. Competitive insights
      • 9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key country dynamic
      • 9.7.3.2. Regulatory framework
      • 9.7.3.3. Competitive insights
      • 9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamic
      • 9.7.4.2. Regulatory framework
      • 9.7.4.3. Competitive insights
      • 9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamic
      • 9.7.5.2. Regulatory framework
      • 9.7.5.3. Competitive insights
      • 9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmacovigilance Market: Competitive Analysis

  • 10.1. Market Participant Categorization
  • 10.2. Public Companies
    • 10.2.1. Company Market Position Analysis
    • 10.2.2. Company Market Share Analysis
  • 10.3. Competitive Factors and Strategies
    • 10.3.1. Increasing Strategic Collaborations and Product Launches
    • 10.3.2. Strategic Government initiatives, including collaborations
    • 10.3.3. Competitors increased PV Awareness programs
    • 10.3.4. Competitors increased collaboration and outsourcing of operations
    • 10.3.5. Consolidation Trends

Chapter 11. Competitive Landscape

  • 11.1. Company Profiles
    • 11.1.1. Accenture
      • 11.1.1.1. Overview
      • 11.1.1.2. Financial performance
      • 11.1.1.3. Product benchmarking
      • 11.1.1.4. Strategic initiatives
    • 11.1.2. IQVIA Inc.
      • 11.1.2.1. Overview
      • 11.1.2.2. Financial performance
      • 11.1.2.3. Product benchmarking
      • 11.1.2.4. Strategic initiatives
    • 11.1.3. Cognizant
      • 11.1.3.1. Overview
      • 11.1.3.2. Financial performance
      • 11.1.3.3. Product benchmarking
      • 11.1.3.4. Strategic initiatives
    • 11.1.4. Clinquest Group B.V. (Linical Americas)
      • 11.1.4.1. Overview
      • 11.1.4.2. Financial performance
      • 11.1.4.3. Product benchmarking
      • 11.1.4.4. Strategic initiatives
    • 11.1.5. IBM
      • 11.1.5.1. Overview
      • 11.1.5.2. Financial performance
      • 11.1.5.3. Product benchmarking
      • 11.1.5.4. Strategic initiatives
    • 11.1.6. Laboratory Corporation of America Holdings
      • 11.1.6.1. Overview
      • 11.1.6.2. Financial performance
      • 11.1.6.3. Product benchmarking
      • 11.1.6.4. Strategic initiatives
    • 11.1.7. ArisGlobal
      • 11.1.7.1. Overview
      • 11.1.7.2. Financial performance
      • 11.1.7.3. Product benchmarking
      • 11.1.7.4. Strategic initiatives
    • 11.1.8. Capgemini
      • 11.1.8.1. Overview
      • 11.1.8.2. Financial performance
      • 11.1.8.3. Product benchmarking
      • 11.1.8.4. Strategic initiatives
    • 11.1.9. ITClinical
      • 11.1.9.1. Overview
      • 11.1.9.2. Financial performance
      • 11.1.9.3. Products & Services benchmarking
      • 11.1.9.4. Strategic initiatives
    • 11.1.10. ICON plc.
      • 11.1.10.1. Overview
      • 11.1.10.2. Financial performance
      • 11.1.10.3. Product benchmarking
      • 11.1.10.4. Strategic initiatives
    • 11.1.11. TAKE Solutions Limited
      • 11.1.11.1. Overview
      • 11.1.11.2. Financial performance
      • 11.1.11.3. Product benchmarking
      • 11.1.11.4. Strategic initiatives
    • 11.1.12. Parexel International (MA) Corporation
      • 11.1.12.1. Overview
      • 11.1.12.2. Financial performance
      • 11.1.12.3. Product benchmarking
      • 11.1.12.4. Strategic initiatives
    • 11.1.13. Wipro
      • 11.1.13.1. Overview
      • 11.1.13.2. Financial performance
      • 11.1.13.3. Product benchmarking
      • 11.1.13.4. Strategic initiatives
    • 11.1.14. United BioSource LLC
      • 11.1.14.1. Overview
      • 11.1.14.2. Financial performance
      • 11.1.14.3. Product benchmarking
      • 11.1.14.4. Strategic initiatives
    • 11.1.15. BioClinica Inc. (Clario)
      • 11.1.15.1. Overview
      • 11.1.15.2. Financial performance
      • 11.1.15.3. Product benchmarking
      • 11.1.15.4. Strategic initiatives
    • 11.1.16. ClinChoice (formerly FMD K&L)
      • 11.1.16.1. Overview
      • 11.1.16.2. Financial performance
      • 11.1.16.3. Product benchmarking
      • 11.1.16.4. Strategic initiatives

Chapter 12. Winning Strategies

  • 12.1. Key Winning / Scoring Criteria
    • 12.1.1. By Categories
      • 12.1.1.1. Pharmaceuticals
      • 12.1.1.2. Biotech companies
      • 12.1.1.3. Medical device companies
    • 12.1.2. Key Vendor Selection Factors
      • 12.1.2.1. By Category
      • 12.1.2.2. BY Company size
          • 12.1.2.2.1.1. Key Takeaways

Chapter 13. Switching Cost Analysis

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. North America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
  • Table 4. North America Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • Table 5. North America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 6. North America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 7. North America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 8. North America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 9. North America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 10. U.S. Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 11. U.S. Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 12. U.S. Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 13. U.S. Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 14. U.S. Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 15. U.S. Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • Table 16. Canada Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 17. Canada Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 18. Canada Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 19. Canada Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 20. Canada Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 21. Canada Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • Table 22. Mexico Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 23. Mexico Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 24. Mexico Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 25. Mexico Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 26. Mexico Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 27. Mexico Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • Table 28. Europe Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 29. Europe Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 30. Europe Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 31. Europe Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 32. Europe Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 33. Europe Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 34. UK Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 35. UK Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 36. UK Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 37. UK Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 38. UK Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 39. UK Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 40. Germany Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 41. Germany Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 42. Germany Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 43. Germany Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 44. Germany Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 45. Germany Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 46. France Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 47. France Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 48. France Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 49. France Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 50. France Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 51. France Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 52. Italy Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 53. Italy Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 54. Italy Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 55. Italy Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 56. Italy Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 57. Italy Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 58. Spain Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 59. Spain Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 60. Spain Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 61. Spain Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 62. Spain Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 63. Spain Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 64. Russia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 65. Russia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 66. Russia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 67. Russia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 68. Russia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 69. Russia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 70. Norway Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 71. Norway Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 72. Norway Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 73. Norway Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 74. Norway Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 75. Norway Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 76. Sweden Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 77. Sweden Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 78. Sweden Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 79. Sweden Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 80. Sweden Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 81. Sweden Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 82. Denmark Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 83. Denmark Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 84. Denmark Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 85. Denmark Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 86. Denmark Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 87. Denmark Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 88. Asia Pacific Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
  • Table 89. Asia Pacific Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 90. Asia Pacific Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 91. Asia Pacific Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 92. Asia Pacific Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 93. Asia Pacific Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 94. Asia Pacific Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • Table 95. Japan Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 96. Japan Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 97. Japan Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 98. Japan Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 99. Japan Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 100. China Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 101. China Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 102. China Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 103. China Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 104. China Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 105. China Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 106. India Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 107. India Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 108. India Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 109. India Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 110. India Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 111. India Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 112. Australia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 113. Australia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 114. Australia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 115. Australia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 116. Australia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 117. Australia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 118. South Korea Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • Table 119. South Korea Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 120. South Korea Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 121. South Korea Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 122. South Korea Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 123. South Korea Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 124. Thailand Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • Table 125. Thailand Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 126. Thailand Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 127. Thailand Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 128. Thailand Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 129. Thailand Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 130. Latin America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
  • Table 131. Latin America Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 132. Latin America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 133. Latin America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 134. Latin America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 135. Latin America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 136. Latin America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 137. Brazil Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 138. Brazil Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 139. Brazil Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 140. Brazil Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 141. Brazil Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 142. Brazil Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 143. Argentina Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 144. Argentina Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 145. Argentina Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 146. Argentina Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 147. Argentina Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 148. Argentina Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 149. Middle East & Africa Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
  • Table 150. Middle East & Africa Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 151. Middle East & Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 152. Middle East & Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 153. Middle East & Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 154. Middle East & Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 155. Middle East & Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 156. South Africa Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • Table 157. South Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 158. South Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 159. South Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 160. South Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 161. South Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 162. Saudi Arabia Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • Table 163. Saudi Arabia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 164. Saudi Arabia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 165. Saudi Arabia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 166. Saudi Arabia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 167. Saudi Arabia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 168. UAE Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 169. UAE Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 170. UAE Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 171. UAE Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 172. UAE Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 173. UAE Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
  • Table 174. Kuwait Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
  • Table 175. Kuwait Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
  • Table 176. Kuwait Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • Table 177. Kuwait Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • Table 178. Kuwait Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 179. Kuwait Pharmacovigilance market, end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmacovigilance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market formulation & validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Market segmentation (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Parent market outlook (In USD Billion)
  • Fig. 14 Related/ancillary market outlook (In USD Billion)
  • Fig. 15 Pharmacovigilance market dynamics
  • Fig. 16 Pharmacovigilance market: Porter's five forces analysis
  • Fig. 17 Pharmacovigilance market: PESTLE analysis
  • Fig. 18 Pharmacovigilance market: product life cycle segment dashboard
  • Fig. 19 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
  • Fig. 20 Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 21 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 22 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 23 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 24 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 25 Pharmacovigilance market: Service provider movement analysis
  • Fig. 26 Pharmacovigilance Service provider dashboard
  • Fig. 27 Pharmacovigilance market: product life cycle segment dashboard
  • Fig. 28 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
  • Fig. 29 In-house market, 2018 - 2030 (USD Million)
  • Fig. 30 contract outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 31 Pharmacovigilance market: Type movement analysis
  • Fig. 32 Pharmacovigilance type dashboard
  • Fig. 33 Pharmacovigilance market: product life cycle segment dashboard
  • Fig. 34 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
  • Fig. 35 Spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 36 Intensified ADR reporting market, 2018 - 2030 (USD Million)
  • Fig. 37 Targeted spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 38 CEM market, 2018 - 2030 (USD Million)
  • Fig. 39 EHR mining market, 2018 - 2030 (USD Million)
  • Fig. 40 Pharmacovigilance market: process flow segment dashboard
  • Fig. 41 Pharmacovigilance market: process flow market share analysis, 2024 & 2030
  • Fig. 42 Case data management market, 2018 - 2030 (USD Million)
  • Fig. 43 Case logging market, 2018 - 2030 (USD Million)
  • Fig. 44 Case data analysis market, 2018 - 2030 (USD Million)
  • Fig. 45 Medical reviewing and reporting market, 2018 - 2030 (USD Million)
  • Fig. 46 Signal detection market, 2018 - 2030 (USD Million)
  • Fig. 47 Adverse event logging market, 2018 - 2030 (USD Million)
  • Fig. 48 Adverse event analysis market, 2018 - 2030 (USD Million)
  • Fig. 49 Adverse event review & reporting market, 2018 - 2030 (USD Million)
  • Fig. 50 Risk management system market, 2018 - 2030 (USD Million)
  • Fig. 51 Risk Evaluation System market, 2018 - 2030 (USD Million)
  • Fig. 52 Risk mitigation system market, 2018 - 2030 (USD Million)
  • Fig. 53 Pharmacovigilance market: therapeutic area segment dashboard
  • Fig. 54 Pharmacovigilance market: therapeutic area market share analysis, 2024 & 2030
  • Fig. 55 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 56 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 57 Cardiology market, 2018 - 2030 (USD Million)
  • Fig. 58 Respiratory systems market, 2018 - 2030 (USD Million)
  • Fig. 59 Others market, 2018 - 2030 (USD Million)
  • Fig. 60 Pharmacovigilance market: end use segment dashboard
  • Fig. 61 Pharmacovigilance market: end use market share analysis, 2024 & 2030
  • Fig. 62 Pharmaceuticals market, 2018 - 2030 (USD Million)
  • Fig. 63 Biotechnology companies' market, 2018 - 2030 (USD Million)
  • Fig. 64 Medical device manufacturers market, 2018 - 2030 (USD Million)
  • Fig. 65 Others market, 2018 - 2030 (USD Million)
  • Fig. 66 Pharmacovigilance market revenue, by region
  • Fig. 67 Regional marketplace: Key takeaways
  • Fig. 68 North America Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 US Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Canada Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Mexico Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Europe Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 UK Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Germany Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 France Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Italy Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Spain Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Norway Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Sweden Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Denmark Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 93 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Japan Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 China Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 India Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Australia Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 South Korea Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Thailand Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 106 Latin America Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Brazil Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Argentina Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 MEA Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 South Africa Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 115 Key country dynamics
  • Fig. 116 Saudi Arabia Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 117 Key country dynamics
  • Fig. 118 UAE Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
  • Fig. 121 Key country dynamics
  • Fig. 122 Company categorization
  • Fig. 123 Company market position analysis
  • Fig. 124 Strategic framework